AstraZeneca Pharma India reported a robust second quarter, with profit rising 41% year-on-year to ₹54.2 crore and revenue up 37%.

Drugmakers feel empowered to resist foreign price controls — confident that the Trump administration will have their backs.

(Reuters) -Several pharmaceutical companies have said they will sell drugs direct to patients in the U.S. and offered ...

AstraZeneca posted its third-quarter and nine-month figures well before market open that day. These revealed that the company ...

AstraZeneca chief exec Pascal Soriot (pictured) said Britain should be trying to attract cash from the pharmaceutical sector ...

Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

AstraZeneca PLC (AZN) reports an 11% revenue increase, driven by oncology and biopharmaceuticals, while navigating R&D ...

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.

Anglo-Swedish pharma major AstraZeneca closed Thursday’s trading 3% higher, as investors digested its third quarter financial ...

AstraZeneca's net profit in Q3 2025 was $2.54 billion, or $1.64 per share, compared to $1.43 billion, or $.92 per share, in Q3 2024. The firm beat the Wall Street consensus EPS estimate of $1.13.

ASTRAZENECA delivered better-than-expected third quarter earnings and retained its full-year forecasts on Thursday, with strong sales of its blockbuster cancer and cardiovascular drugs.